- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03728881
Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer")
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVE:
I. To demonstrate that the immunogenicity (as determined by enzyme-linked immunosorbent assay [ELISA]) of a single dose of recombinant human papillomavirus bivalent vaccine (Cervarix) in 9-14 year old girls is non-inferior to the immunogenicity of three doses of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil), administered at 0, 2, and 6 months, in 18-25 year old women 36 months after initial vaccination, with an interim analysis at 24 months after initial vaccination.
SECONDARY OBJECTIVES:
I. To compare the distribution of HPV -16 and HPV-18 antibodies levels, assessed at 24 and 36 months after initial vaccination, following a single dose of Cervarix in 9-14 year old girls and three doses of Gardasil, administered at 0, 2, and 6 months, in 18-25 year old women.
II. To compare rates of seroconversion based on HPV-16 and HPV-18 antibody levels, assessed at 24 and 36 months after initial vaccination, following a single dose of Cervarix in 9-14 year old girls and three doses of Gardasil, administered at 0, 2, and 6 months, in 18-25 year old women.
III. To compare geometric mean titers (GMTs), distributions, and seroconversion rates for HPV-16 and HPV-18 antibodies, assessed at 24 and 36 months after initial vaccination, following a single dose of Cervarix in 9-11 year old girls and three doses of Gardasil, administered at 0, 2, and 6 months, in 18-25 year old women; to perform a similar comparison restricting to 12-14 year old girls.
IV. To compare GMTs, distributions, and seroconversion rates for HPV-16 and HPV-18 antibodies, assessed at 1-month after vaccination and 1-year after vaccination, following a single dose of Cervarix in 9-10 year old girls and a single dose of Cervarix in 11-14 year old girls.
V. To evaluate whether baseline variables (e.g. geographic district, initial antibody levels, date of vaccination) are associated with GMTs, distributions, and seroconversion rates for HPV16 and HPV-18 antibodies, assessed at 24 and 36 months after initial vaccination.
OUTLINE: Participants are assigned to 1 of 2 groups.
GROUP I: Participants 9-14 years old receive Cervarix intramuscularly (IM) at baseline.
GROUP II: Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
After completion of trial vaccine dose(s), participants are followed up at 1, 12, 24, and 36 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guanacaste
-
Liberia, Guanacaste, Costa Rica, 50101
- Agencia Costarricense de Investigaciones Biomédicas (ACIB)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Aged between:
- 9 and 14 years inclusive for Cervarix group
- 18 and 25 years inclusive for Gardasil group
- Living in the study area without plans to move outside the country in the next six months
- Able to communicate with study personnel
- Able and willing to provide a blood sample
- Willing to permit export of blood samples to the United States
Willing to participate in the study and:
- If Cervarix group and less than 12 years old, receive study information and be supported in study participation by at least one of parent (or guardian), who is willing to sign the informed consent document
- If Cervarix group and 12 years old or older, sign the informed assent and be supported in study participation by at least one parent (or guardian), who is willing to sign the informed consent document
- If Gardasil group, sign the informed consent
- In good health as determined by a medical history (physical exam will be conducted if necessary per the doctor's criterion)
Exclusion Criteria:
- They have a diagnosis of an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and / or adequate control that, according to the principal investigator or designee, for which vaccination is contraindicated (NOTE: Potential participants with these conditions can be included after consultation with the external medical advisor of the study or with an appropriate specialist)
- They are allergic to one of the vaccine components, including yeast (if Gardasil group)
- They have received immunoglobulins within 90 days preceding enrollment/vaccination visit
- They are unwilling to provide a blood sample
- Unwilling to permit export of blood samples to the United States
- They have a positive urine pregnancy test result
- They are pregnant
- They are planning to become pregnant
- The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation
- They have been vaccinated against HPV
- The participant or her parent/legal guardian, as applicable, does not have an identification document
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (Cervarix)
Participants 9-14 years old receive Cervarix IM at baseline.
|
Given IM
Other Names:
|
Active Comparator: Group II (Gardasil)
Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
|
Given IM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Human papillomavirus (HPV) 16 antibody level
Time Frame: At 24 months after initial vaccination
|
Will measure HPV-16 specific serum antibody using the HPV type-specific enzyme-linked immunoassay (ELISA) on serum.
Will estimate the two-sided 99% confidence interval of the geometric mean titer (GMT) ratios for HPV-16 and HPV-18 at 24 months and the two-sided 96% confidence intervals of the GMT ratios for HPV-16 and HPV-18 at 36 months.
|
At 24 months after initial vaccination
|
HPV-16 antibody level
Time Frame: At 36 months after initial vaccination
|
Will measure HPV-16 specific serum antibody using the HPV type-specific ELISA on serum.
Will estimate the two-sided 99% confidence interval of the GMT ratios for HPV-16 and HPV-18 at 24 months and the two-sided 96% confidence intervals of the GMT ratios for HPV-16 and HPV-18 at 36 months.
|
At 36 months after initial vaccination
|
HPV-18 antibody level
Time Frame: At 24 months after initial vaccination
|
Will measure HPV-18 specific serum antibody using the HPV type-specific ELISA on serum.
Will estimate the two-sided 99% confidence interval of the GMT ratios for HPV-16 and HPV-18 at 24 months and the two-sided 96% confidence intervals of the GMT ratios for HPV-16 and HPV-18 at 36 months.
|
At 24 months after initial vaccination
|
HPV-18 antibody level
Time Frame: At 36 months after initial vaccination
|
Will measure HPV-18 specific serum antibody using the HPV type-specific ELISA on serum.
Will estimate the two-sided 99% confidence interval of the GMT ratios for HPV-16 and HPV-18 at 24 months and the two-sided 96% confidence intervals of the GMT ratios for HPV-16 and HPV-18 at 36 months.
|
At 36 months after initial vaccination
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2020-07432 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 999919009
- 19-C-N009 (Other Identifier: National Cancer Institute)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papillomavirus-Related Cervical Carcinoma
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Human Papillomavirus-Related Malignant NeoplasmUnited States
-
Institut de Cancérologie de LorraineCompletedHuman Papillomavirus-Related Cervical CarcinomaFrance
-
National Cancer Institute (NCI)Active, not recruitingCervical Carcinoma | Oral Cavity Carcinoma | Human Papillomavirus Infection | Anal Carcinoma | Human Papillomavirus-Related Cervical CarcinomaCosta Rica
-
National Cancer Institute (NCI)Not yet recruitingHuman Papillomavirus-Related CarcinomaUnited States, Austria
-
Fred Hutchinson Cancer CenterRecruitingHuman Papillomavirus-Related CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
University of MichiganCompletedHuman Papillomavirus-Related CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related CarcinomaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingHuman Papillomavirus-Related Carcinoma | Human Papillomavirus Positive Oropharyngeal Carcinoma | Human Papillomavirus Positive Cervical Carcinoma | Human Papillomavirus Positive Anal Carcinoma | Human Papillomavirus Positive Vulvar Carcinoma | Human Papillomavirus Positive Penile CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCervical Intraepithelial Neoplasia | Uterine Cervical Neoplasms | Human Papillomavirus 16 | Human Papillomavirus 18Nigeria
Clinical Trials on Recombinant Human Papillomavirus Bivalent Vaccine
-
National Cancer Institute (NCI)Bill and Melinda Gates FoundationEnrolling by invitationHuman Papillomavirus Infection | Human Papillomavirus-Related Cervical CarcinomaCosta Rica
-
National Cancer Institute (NCI)Active, not recruitingCervical Carcinoma | Human Papillomavirus InfectionCosta Rica
-
Shanghai Zerun Biotechnology Co.,LtdYuxi Zerun Biotechnology Co., Ltd.Completed
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaboratorsActive, not recruitingHIV InfectionPeru, Brazil, Haiti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant RecipientUnited States
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...RecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
University Hospital Virgen de las NievesInstituto de Salud Carlos IIIUnknownHIV Infections | HPV InfectionSpain
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...RecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina